Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.84 USD
+0.07 (1.47%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.72 -0.12 (-2.48%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Lipocine Inc. [LPCN]
Reports for Purchase
Showing records 61 - 80 ( 106 total )
Company: Lipocine Inc.
Industry: Medical - Drugs
Agreement Over LPCN 1107''s (Oral 17- HPC) Phase 3 In Pre-Term Birth
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
FDA Guidance Provides Path for What Would Be First Approved Oral for Prevention of Preterm Birth
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING - MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Dosing Flexibility Study Added to 1021s NDA; 1107 Update Soon
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
1021''s Post-CRL Starting; Results 2Q''17; Size Does Matter
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Revisiting the high points on low-T with LPCN 1021
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
FDA Agreeing to a Small and Brief Post-CRL Trial With LPCN-1021
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Clear Path for ''1021 Approval With Short Dosing Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
It Puts Hair on Your Chest; Initiate With $25 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
With LPCN 1111''s Positive Ph2b Results, Pipeline Outlook to Stiffen in 4Q
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
With Two FDA Mtgs - Ph2b Data, 2H''16 to Establish Lipocine''s Identity
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.